Advanced Therapeutics Journal Cover Design Service (eMVs)

Advanced Therapeutics
14 June 2023
Peptide-Decorated Artificial Erythrocyte Microvesicles Endowed with Lymph Node Targeting Function for Drug Delivery
Gan Zhang^1,2, Wenjing Cheng^1,2, Ni Yang^1,2,, Baoye Yang^1,2, Shi Yu^1,2, Jing Zheng^1,2, Miaomiao Li^1,2, Yaling Fu^1,2, Xinzhi Li^1,2, Yinhong Song^1,2, Zhihong Zhang^3,4 and Xiang Yu^1,2,3
¹ Hubei Key Laboratory of Tumor Microenvironment and Immunotherapy, China Three Gorges University, Yichang, 443002 China

² Medical College, China Three Gorges University, Yichang, 443002 China

³ School of Biomedical Engineering, Hainan University, Haikou, 570228 China

⁴ Britton Chance Center for Biomedical Photonics, Wuhan National Laboratory for Optoelectronics-Huazhong University of Science and Technology, Wuhan, 430074 China

^† G.Z., W.C., and N.Y. contributed equally to this work.
10.1002/adtp.202200236
In article number 2200236, Zhihong Zhang, Xiang Yu, and co-workers achieve the direct size conversion of erythrocyte-derived MVs (eMVs) via incubation with an ApoA-I mimetic peptide (R4F) capable of binding phospholipids. R4F peptide modification endows eMVs with SR-B1 receptor and lymph node targeting functions, providing an excellent drug delivery system for the targeted treatment of lymph node-associated diseases.